Cargando…

Molecular targeted therapies in metastatic melanoma

The advent of personalized medicine has ushered in a new era for cancer therapy with a significant impact on the management of advanced melanoma. Molecular targeted therapies have shown promise in the management of various malignancies, including melanoma, with lower toxicity profiles and better ove...

Descripción completa

Detalles Bibliográficos
Autores principales: Chakraborty, Rima, Wieland, Carilyn N, Comfere, Nneka I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3702032/
https://www.ncbi.nlm.nih.gov/pubmed/23843700
http://dx.doi.org/10.2147/PGPM.S44800
_version_ 1782275746403713024
author Chakraborty, Rima
Wieland, Carilyn N
Comfere, Nneka I
author_facet Chakraborty, Rima
Wieland, Carilyn N
Comfere, Nneka I
author_sort Chakraborty, Rima
collection PubMed
description The advent of personalized medicine has ushered in a new era for cancer therapy with a significant impact on the management of advanced melanoma. Molecular targeted therapies have shown promise in the management of various malignancies, including melanoma, with lower toxicity profiles and better overall survival as compared with conventional therapy. The discovery of BRAF mutations in melanoma led to the development of BRAF inhibitors for the treatment of advanced melanoma. However, growing concerns over drug resistance to molecular targeted therapies including BRAF inhibitors, have spurred efforts to elucidate additional molecular targets for the treatment of advanced melanoma. In this review, we discuss the known molecular aberrations in melanoma, current and novel targeted approaches in its treatment, and drug resistance patterns.
format Online
Article
Text
id pubmed-3702032
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-37020322013-07-10 Molecular targeted therapies in metastatic melanoma Chakraborty, Rima Wieland, Carilyn N Comfere, Nneka I Pharmgenomics Pers Med Review The advent of personalized medicine has ushered in a new era for cancer therapy with a significant impact on the management of advanced melanoma. Molecular targeted therapies have shown promise in the management of various malignancies, including melanoma, with lower toxicity profiles and better overall survival as compared with conventional therapy. The discovery of BRAF mutations in melanoma led to the development of BRAF inhibitors for the treatment of advanced melanoma. However, growing concerns over drug resistance to molecular targeted therapies including BRAF inhibitors, have spurred efforts to elucidate additional molecular targets for the treatment of advanced melanoma. In this review, we discuss the known molecular aberrations in melanoma, current and novel targeted approaches in its treatment, and drug resistance patterns. Dove Medical Press 2013-06-07 /pmc/articles/PMC3702032/ /pubmed/23843700 http://dx.doi.org/10.2147/PGPM.S44800 Text en © 2013 Chakraborty et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Chakraborty, Rima
Wieland, Carilyn N
Comfere, Nneka I
Molecular targeted therapies in metastatic melanoma
title Molecular targeted therapies in metastatic melanoma
title_full Molecular targeted therapies in metastatic melanoma
title_fullStr Molecular targeted therapies in metastatic melanoma
title_full_unstemmed Molecular targeted therapies in metastatic melanoma
title_short Molecular targeted therapies in metastatic melanoma
title_sort molecular targeted therapies in metastatic melanoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3702032/
https://www.ncbi.nlm.nih.gov/pubmed/23843700
http://dx.doi.org/10.2147/PGPM.S44800
work_keys_str_mv AT chakrabortyrima moleculartargetedtherapiesinmetastaticmelanoma
AT wielandcarilynn moleculartargetedtherapiesinmetastaticmelanoma
AT comferennekai moleculartargetedtherapiesinmetastaticmelanoma